AtriCure (ATRC) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AtriCure (ATRC) has outperformed NovoCure (NVCR) over the past year, gaining 50.6% versus a loss of 0.9%. Over five years, ATRC leads with a -26.0% price change compared with -87.3% for NVCR. AtriCure is the larger company by market cap ($2.69 billion vs $1.66 billion), about 1.6 times the size.
AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -20.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | NVCR |
|---|---|---|
| Share price | $52.84 | $14.22 |
| Market cap | $2.69B | $1.66B |
| 1-day change | -0.88% | -3.00% |
| YTD return | +33.57% | +9.98% |
| 1-year return | +50.63% | -0.91% |
| 5-year return | -25.96% | -87.33% |
| P/E ratio (TTM) | 251.62 | — |
| Forward P/E | 121.76 | — |
| EPS (TTM) | $0.21 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $655.35M |
| Revenue growth (YoY) | +14.88% | +8.28% |
| Net income (latest FY) | $-11.45M | $-136.23M |
| Gross margin | 74.98% | 74.54% |
| Operating margin | -1.77% | -23.47% |
| Net margin | -2.14% | -20.79% |
| 52-week high | $61.70 | $21.45 |
| 52-week low | $25.36 | $9.82 |
| Distance from 52-week high | -14.36% | -33.71% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.88% | +88.89% |
| Average volume | 1.08M | 1.42M |
| Shares outstanding | 50.87M | 116.45M |
| Employees | 1,350 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed NVCR by 51.5 percentage points over the past year.
- AtriCure is more profitable, keeping -2.1 cents of every revenue dollar as net income versus -20.8 cents for NovoCure.
- AtriCure grew revenue faster in its latest fiscal year (+14.88% vs +8.28%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
ATRC vs NVCR FAQ
Which is bigger, AtriCure or NovoCure?
AtriCure (ATRC) is larger, with a market capitalization of $2.69B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, ATRC or NVCR?
ATRC returned +50.63% over the past 12 months, compared with -0.91% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and NovoCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.